Retatrutide phase 3 trials show reduced pain, improved mobility in knee osteoarthritis with obesity

Two phase 3 trials in NEJM report that retatrutide, a GLP-1/GIP/glucagon receptor agonist, reduced pain and improved mobility in obese patients with knee osteoarthritis. This expands the drug's potential beyond weight loss to a major cause of disability in older adults. Regulatory and reimbursement implications remain uncertain.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works